Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
(WorldNews Health)

New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results from a pooled analysis of two Phase 3 studies, show that patients treated with Cosentyx (n=477) had a faster time to complete resolution of enthesitis than those receiving placebo (n=235) [2] Both Cosentyx 300 mg and 150 mg...